Anti-CD19 CAR-T products (axi-cel, liso-cel, and tisagenlecleucel [tisa-cel]) were initially FDA approved for R/R DLBCL in the third line setting [11, 61, 62] and more recently (axi-cel and liso-cel) in the second line setting [12, 63]. Here, CD19 is linked to diffuse large B-cell lymphoma.